The Journal of Experimental Medicine
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online February 12, 2007
doi:10.1084/jem.20070104
The Journal of Experimental Medicine, Vol. 204, No. 2, 239-243
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Trinchieri
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trinchieri, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trinchieri, G.
Related Collections
Right arrowRelated Articles
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

COMMENTARY

Interleukin-10 production by effector T cells: Th1 cells show self control

Giorgio Trinchieri

CORRESPONDENCE G.T.: trinchig{at}mail.nih.gov


ABSTRACT
Interleukin (IL)-10 is a cytokine that modulates both innate and adaptive immunity, primarily by exerting antiinflammatory effects. IL-10 was originally thought to be produced only by T helper (Th)2 cells, but is now known to be made by a variety of cell types. During many infections, CD4+ T cells produce both interferon (IFN)-{gamma}, the signature Th1 cytokine, and IL-10. New data now show that the IL-10 produced by effector Th1 cells helps limit the collateral damage caused by exaggerated inflammation. But this control may also limit the effectiveness of the immune response, resulting in a failure to fully eliminate pathogens.


G.T. is at Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles

CD4+CD25Foxp3 Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis
Charles F. Anderson, Mohammed Oukka, Vijay J. Kuchroo, and David Sacks
J. Exp. Med. 2007 204: 285-297. [Abstract] [Full Text] [PDF]

Conventional T-bet+Foxp3 Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection
Dragana Jankovic, Marika C. Kullberg, Carl G. Feng, Romina S. Goldszmid, Carmen M. Collazo, Mark Wilson, Thomas A. Wynn, Masahito Kamanaka, Richard A. Flavell, and Alan Sher
J. Exp. Med. 2007 204: 273-283. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS